You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Lexmark International, Inc. v. Impression Products, Inc. (Fed. Cir. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Lexmark International, Inc. v. Impression Products, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Lexmark International, Inc. v. Impression Products, Inc. | 14-1617

Last updated: February 9, 2026

Case Overview

Lexmark International, Inc. sued Impression Products, Inc. for repair and resale activities involving Lexmark’s patented toner cartridges. The dispute centered on whether Lexmark could establish patent rights on products after they were sold, and whether patent rights could be exhausted through authorized resale. The Supreme Court granted certiorari to resolve circuit conflicts on these issues.

Court’s Holding

The Supreme Court ruled in favor of Impression Products, invalidating Lexmark's patent rights post-initial sale, regardless of the nature of the sale. The Court held that patent rights are exhausted after the first authorized sale and that patent rights cannot be reinvoked through patent law to control subsequent resale or reuse.

Key Issues

  1. Patent Exhaustion Doctrine: Does an authorized sale of a patented item exhaust the patent holder's rights, preventing patent enforcement after the sale?
  2. Restrictions on Repairs and Reuse: Can patent rights be used to restrict repair, resale, or reuse of a patented product after sale?
  3. Jurisdictional Conflict: Does federal law preempt state restrictions on resale, and can patent rights be extended to control downstream transactions?

Decision Details

Majority Opinion

Justice Kagan authored the opinion, emphasizing that patent rights are exhausted after an authorized sale. The Court analyzed the distinction between patent rights and copyright restrictions, ruling that the patent exhaustion doctrine applies broadly, regardless of whether the sale is authorized or whether restrictions are imposed.

Key points:

  • The First Sale Doctrine applies to patents, just as it does to copyrights.
  • Lexmark’s restrictions, including warranties limiting repairs or resale, do not override patent exhaustion.
  • Patent rights do not permit patent owners to control the use or resale of an invention after the initial authorized sale.

Dissenting Opinions

Justices Thomas and Alito dissented, arguing that patent rights should allow patent holders to impose restrictions on resale and reuse, especially when restrictions are part of an authorized sale.

Implications for Patent Law and Business Practices

  • Patent Exhaustion Limits Enforcement: Patent holders cannot impose post-sale restrictions via patent law once the product is sold with authorization.
  • Impact on Repair and Resale Markets: Companies cannot enforce patent rights to prevent third-party repair, refurbishment, or resale of patented products following authorized distribution.
  • Preemption of State Law: The ruling clarifies that federal patent law preempts state laws attempting to impose resale restrictions.

Industry Impact

The ruling supports secondary markets for patented products, including repairs, reconditioning, and resale. Companies like Lexmark that previously sought to restrict these activities face legal limits under patent law. Patent holders must rely on contracts or licensing rather than patent rights to control downstream activities post-sale.

Summary Table

Aspect Key Points
Patent Exhaustion Occurs upon authorized first sale, precluding patent rights' enforcement afterwards
Post-Sale Restrictions Patent rights cannot be used to restrict reuse or resale after a sale
Federal vs. State Law Federal patent law preempts state restrictions on resale or reuse
Remedies for Patent Owners Must rely on contractual agreements rather than patent rights

Key Takeaways

  • Patent exhaustion applies after an authorized sale, ending patent rights.
  • Restrictions on resale or reuse cannot be enforced through patent rights once the product is sold.
  • The ruling aligns U.S. patent law with practices in copyright law concerning the First Sale Doctrine.
  • The decision limits patent owners’ ability to control secondary markets post-sale.
  • Companies must craft contractual restrictions to regulate downstream activities if desired.

FAQs

1. How does this decision affect patent licensing?
It limits the scope of restrictions patent holders can enforce post-sale, prompting reliance on licensing agreements rather than patent rights for control over resale or repair.

2. Can patent owners still prevent unauthorized copying?
Yes, patent owners retain rights to prevent infringing manufacturing or copying. The ruling only affects restrictions on resale or reuse after an authorized sale.

3. Does this ruling apply to all types of patented products?
The ruling applies broadly to all patented tangible goods, including consumer electronics, machinery, and medical devices.

4. How does this decision compare to copyright law?
It aligns patent law with copyright law, where the First Sale Doctrine limits restrictions following authorized distribution.

5. Can companies prevent repair or refurbishment through contracts?
Yes, contractual agreements, warranties, or licensing can impose restrictions independent of patent rights, but patent law itself cannot enforce such restrictions post-sale.

References

  1. Lexmark International, Inc. v. Impression Products, Inc., 583 U.S. ___ (2017).
  2. U.S. Supreme Court, Lexmark International, Inc. v. Impression Products, Inc., Docket No. 14-1617.
  3. Patent Law and Exhaustion Doctrine, 35 U.S.C. § 271.
  4. Licensing and Post-Sale Restrictions, USPTO Guidelines.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.